Today’s Solutions: May 24, 2022

There are about 12,200 new head and neck cancer cases in the UK every year, and many of these patients are diagnosed at advanced stages when the disease is very difficult to treat. The standard treatment currently offered to many patients with advanced cancer is “extreme” chemotherapy, which can have serious side effects. A recent medical breakthrough, however, could offer better, kinder treatments for these patients and increase their chances of survival.

As part of a landmark trial, a cocktail of immunotherapy medications employed patients’ immune systems to kill cancer cells in their body and prompted “a positive trend in survival,” according to scientists at the Institute of Cancer Research (ICR), London, and the Royal Marsden NHS foundation trust.

A patient who was expected to pass away four years ago was elated to hear the good news that only weeks after he joined the study, his tumor had “completely disappeared,” he told The Guardian. The 77-year-old man is now cancer-free and spent and enjoyed last week on a cruise off the coast of the UK with his wife.

The new treatment consists of a combination of nivolumab and ipilimumab medications, which proved to reduce the size of tumors in the terminally ill head and neck cancer patients. In some cases, the doctors were surprised to find no detectable sign of disease, as the tumor vanished altogether.

In addition to boosting the long-term survival chances of patients, the treatment also prompted far fewer side effects compared with the often grueling nature of chemotherapy.

Though the ICR said the results from the phase 3 trial, involving almost 1,000 dying head and neck cancer patients, were early and not statistically significant, they were still “clinically meaningful,” with some patients living months and even years longer and suffering fewer side effects.

“Despite the lack of statistical significance, these results are clinically meaningful,” said Prof Kevin Harrington, professor of biological cancer therapies at the ICR, who led the CheckMate 651 trial. “We will need to do a longer follow-up to see whether we can demonstrate a survival benefit across all patients in the trial.”

Solutions News Source Print this article
More of Today's Solutions

How the Belize Barrier Reef is coming back to life

When Hurricane Iris hit Belize in 2001, it ravaged almost all of the country’s coral reefs. The devastation signaled bad news not only for the surrounding marine life but also for the local communities who ... Read More

Redwoods grow new leaves to adapt to drought

We’re doing a lot to adapt to climate change, from creating tree cities and sponge cities to speeding up the schedule for renewable energy. As it turns out, though, humans aren’t the only ones getting ... Read More

OnePower: bringing minigrids and power to Lesotho

A key aspect of helping the developing world is not only ensuring that they have sufficient power and infrastructure to run key facilities like schools and hospitals. It is also important to ensure that their ... Read More

Active UK professional footballer comes out as gay—the first in 30 years

Earlier this month, 17-year-old Jake Daniels, a forward for Blackpool FC in England’s second tier, came out publicly as gay in a statement released by the club. According to the British LGBTQ advocacy group Stonewall, ... Read More

Flow batteries could help with renewable energy storage

The generation of renewable energy from sources like wind and solar is one thing, but there are many other factors to consider when delivering renewable energy to consumers. A big one is the issue of ... Read More

Don’t let ADHD prevent you from meditating. Here are 8 tips for mindful...

We’ve written quite often about the benefits of mindfulness and meditation, but we also recognize that it is sometimes a difficult practice to get into. Meditation is an active process that trains the brain to ... Read More